Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15034180 | 0.84 | MAPT (0.49) | USP30P2RX7BRD4ALDH1A1KMT2A | |
| SCHEMBL17627029 | 0.82 | PRMT5 (0.35) | BRD4ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL10141573 | 0.81 | USP30 (0.43) | USP30P2RX7BRD4ALDH1A1KMT2A | |
| SCHEMBL17627070 | 0.77 | KDM4E (0.56) | ALDH1A1KMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL16061307 | 0.77 | MARS1 (0.55) | USP30CYP1A2 | |
| SCHEMBL10174369 | 0.77 | USP30 (0.40) | USP30P2RX7BRD4ALDH1A1KMT2A | |
| SCHEMBL17076686 | 0.75 | GRIN1 (0.44) | P2RX7ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL16832680 | 0.75 | KDM4E (0.62) | P2RX7ALDH1A1KMT2AMEN1PKM | |
| SCHEMBL15164078 | 0.75 | ADORA2A (0.40) | CYP1A2CYP2C19 | |
| SCHEMBL3185325 | 0.74 | PTGS1 (0.45) | P2RX7KMT2AMEN1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2244706-B1 | GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2016-04-06 | — | — | EP | claimed |
| EP-2244706-A1 | GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-11-03 | — | — | EP | claimed |
| WO-2009106203-A1 | GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | claimed |
| EP-2999338-B1 | KNOWN AND NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2244706-B1 | GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2016-04-06 | — | — | EP | disclosed |
| EP-2197849-B1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-8236824-B2 | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-08-07 | — | — | US | disclosed |
| EP-2244706-A1 | GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-11-03 | — | — | EP | disclosed |
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-2197849-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009106203-A1 | GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009046802-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | GCKR, HK1, GCK | USP30 3977/4885P2RX7 1157/4885BRD4 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.